
About Raphas
Raphas is a publicly listed company based in Seoul (South Korea) founded in 2006. Microneedle technology is developed for cosmetics and medical applications. The company has 100 employees. Its focus areas include Life Sciences, Drug Delivery, Patches and Microneedle Patch.
Company details
Developer of microneedle technology for cosmetics and medical applications. This company manufactures microneedles for transdermal drug delivery and produces cosmetic and food products utilizing this technology. The company holds various certifications and approvals for its products in multiple regions. Its offerings include a cosmetic brand featuring microneedle technologies and a brand of health-focused food products.
- Headquarters Seoul, South Korea
- Employees 100
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website raphas.com
- Legal Name Raphas Co. Ltd.
- Annual Revenue$21.46 M (USD)13.86as on Dec 31, 2025
- Net Profit-$2.98 M (USD)9.58as on Dec 31, 2025
- EBITDA$207.89 K (USD)61.96as on Dec 31, 2025
- Investors
- Employee Count100
Funding Insights of Raphas
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of Raphas with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2016 | Seed | β | β |
1 investors in total: 1 institutional.
Investors in Raphas
Raphas has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include KIC Europe.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
KIC Europe is focused on fostering innovation between Korea and the EU. | kiceurope.eu | Berlin, Germany |
Investor details for Raphas
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of Raphas
Raphas is a publicly listed company on the KRX with ticker symbol 214260 in South Korea, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date11 Nov 2019
- Listed onKRX: 214260
- Listed entityRAPHAS CO. LTD.
- Exchange sectorProcess industries
- ISINKR7214260002
- Share price7,140.00 KRW (+0.56% on the day) · 2026-10-14
- Market capitalisation59,700,083,923.00 KRW
- Price to earnings200.0
- EPS (diluted, trailing year)-651.66 KRW
- Volume (last session)4,231
Financials of Raphas
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 30.99B KRW | -4.31B KRW | 300.2M KRW |
| 2024 | 27.22B KRW | -4.77B KRW | 185.4M KRW |
| 2023 | 27.94B KRW | -8.80B KRW | -800.5M KRW |
| 2022 | 23.64B KRW | -8.51B KRW | -3.72B KRW |
| 2021 | 20.34B KRW | 4.93B KRW | 198.3M KRW |
Detailed financial statements for Raphas
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Raphas
3 dated milestones of Raphas across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Raphas is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
Web traffic of Raphas
The website of Raphas (raphas.com) receives about 7.1K visits a month and ranks #2,860,048 among all websites worldwide, #3,832 in Biotechnology and Pharmaceuticals.
- Monthly visits7.1K
▼ 2.6% vs previous month
- Unique visitors3.2K
per month
- Global rank#2,860,048
among all websites
- Category rank#3,832
Health · Biotechnology and Pharmaceuticals
- Bounce rate34%
- Pages per visit1.7
- Average visit11 sec
- DevicesDesktop 27% Β· Mobile 73%
Websites whose visitors overlap most with Raphas. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| pharmnews.com | 100% | #274,610 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Raphas
Complete news archive for Raphas
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Raphas
Raphas was founded in 2006 and raised its 1st funding round 10 years after it was founded.
Raphas is headquartered in Seoul, South Korea.
Raphas has 100 employees.
Annual revenue of Raphas is $21.46M as on Dec 31, 2025.
Developer of microneedle technology for cosmetics and medical applications. This company manufactures microneedles for transdermal drug delivery and produces cosmetic and food products utilizing this technology. The company holds various certifications and approvals for its products in multiple regions. Its offerings include a cosmetic brand featuring microneedle technologies and a brand of health-focused food products.
Yes, Raphas is publicly traded on KRX under the ticker symbol 214260.
Raphas has 1 investor. Key investors include KIC Europe.
